Duboce Biopharmaceuticals

Duboce Biopharmaceuticals is a pre-clinical stage biotechnology company focused on developing oral small molecule inhibitors for the treatment of autoimmune and inflammatory diseases. The company's primary focus is on targeting the IL-17 pathway, which is a clinically validated driver of conditions such as psoriasis and psoriatic arthritis. By developing oral alternatives to existing injectable biologic therapies, Duboce aims to improve patient convenience and access to effective treatments. The company is led by an experienced management team with a track record in drug discovery and development within the immunology space.